
Octagon Winds Down After Deprioritizing Lead Program
Following the deprioritization of a lead B cell immunomodulator program and unresolved biology questions around a high-potential pipeline effort, Octagon Therapeutics is winding down operations, its CEO and co-founder announced Monday on LinkedIn. “Over …